Sign in

SXTP on Nasdaq

60 DEGREES PHARMACEUTICALS, INC.

American pharmaceutical preparations company based in Washington1

In its 2026 annual report the company says: “We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019.”8 Its shares trade on Nasdaq under the symbol SXTP.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Galena Biopharma, Kitov Pharma or Shattuck Labs, Inc., or pick any stock.

  • TickerSXTP on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWashington, the District of Columbia1
  • Incorporated inDE2
  • Business address1025 Connecticut Avenue Nw, Suite 1000, Washington, Dc 200362
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

22.3%Gross margin3
-771.6%Operating margin3
-732.5%Net margin3
65.5%Revenue growth, 20253
-212.7%Return on equity3
0.04×Debt to equity3
-$7.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue27¢$781.7K
  • Research and development73¢$2.1M

Out of $1.0M in revenue.3 The company lost money this year.

Financial statements

Revenue453$1.0M in 2025+350% since 2022
0$500.0K$1.0M$1.5M2022: $223.2K$223.2K20222023: $253.6K$253.6K2023+14%2024: $607.6K$607.6K2024+140%2025: $1.0M$1.0M2025+65%
Gross profit453$223.8K in 2025
-$400.0K-$200.0K0$200.0K$400.0K2022: -$209.2K-$209.2K20222023: -$221.0K-$221.0K2023+6%2024: $222.8K$222.8K20242025: $223.8K$223.8K2025+0%
Operating income453-$7.8M in 2025+343% since 2022
-$10.0M-$7.5M-$5.0M-$2.5M02022: -$1.8M-$1.8M20222023: -$5.2M-$5.2M2023+194%2024: -$9.7M-$9.7M2024+88%2025: -$7.8M-$7.8M2025−20%
Net income453-$7.4M in 2025+19% since 2022
-$8.0M-$6.0M-$4.0M-$2.0M02022: -$6.2M-$6.2M20222023: -$3.8M-$3.8M2023−39%2024: -$7.9M-$7.9M2024+111%2025: -$7.4M-$7.4M2025−7%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Product Revenues net of Discounts and Rebates$1.0M$607.6K
Cost of Revenues$781.7K$384.8K
Gross Profit$223.8K$222.8K
Research Revenues$403.6K$73.8K
Net Revenue$627.4K$296.6K
Research and Development$2.1M$5.0M
General and Administrative Expenses$6.3M$5.0M
Total Operating Expenses$8.4M$10.0M
Loss from Operations-$7.8M-$9.7M
Interest Expense-$7.8K-$7.9K
Change in Fair Value of Derivative Liabilities$266.1K$1.7M
Other Income, net$132.0K$101.5K
Total Interest and Other Income (Expense), net$390.3K$1.8M
Loss from Operations before Provision for Income Taxes-$7.4M-$8.0M
Provision for Income Taxes (Note 9)$0$0
Net Loss Noncontrolling Interest-$3.2K-$8.6K
Net Loss attributed to 60 Degrees Pharmaceuticals, Inc.-$7.4M-$7.9M
Net Loss-$7.4M-$8.0M
Unrealized Foreign Currency Translation Gain (Loss)$7.1K-$90
Total Comprehensive Loss-$7.4M-$8.0M
Net Loss Noncontrolling Interest-$3.2K-$8.6K
Comprehensive Loss attributed to 60 Degrees Pharmaceuticals, Inc.-$7.4M-$7.9M
Cumulative Dividends on Series A Preferred Stock-$501.1K-$483.3K
Net Loss - attributed to common stockholders-$7.9M-$8.4M
Basic (in Dollars per share)-$11.73-$74.17
Diluted (in Dollars per share)-$11.73-$74.17
Basic (in Shares)670.2K shares113.7K shares
Diluted (in Shares)670.2K shares113.7K shares

Compare 60 DEGREES PHARMACEUTICALS, INC. with another company

Corporate structure

60 DEGREES PHARMACEUTICALS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of 60 DEGREES PHARMACEUTICALS, INC.

  • Lind Global Fund III LP Filed SCHEDULE 13G on 60 DEGREES PHARMACEUTICALS, INC., latest Aug 5, 2026
  • Knight Therapeutics Filed SCHEDULE 13G on 60 DEGREES PHARMACEUTICALS, INC., latest Jul 29, 2026 (3 filings since Nov 13, 2024)
  • CVI Investments, Inc. Filed SCHEDULE 13G/A on 60 DEGREES PHARMACEUTICALS, INC., latest May 15, 2026 (3 filings since Jul 22, 2025)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on 60 DEGREES PHARMACEUTICALS, INC., latest May 13, 2026 (5 filings since Feb 3, 2025)
  • Ayrton Capital LLC Filed SCHEDULE 13G/A on 60 DEGREES PHARMACEUTICALS, INC., latest Nov 13, 2025 (2 filings since May 14, 2025)
  • Orca Capital AG Filed SCHEDULE 13G/A on 60 DEGREES PHARMACEUTICALS, INC., latest Jul 17, 2025 (2 filings since Jul 17, 2025)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on 60 DEGREES PHARMACEUTICALS, INC., latest May 15, 2025 (3 filings since Nov 14, 2024)
  • KNIGHT THERAPEUTICS INTERNATIONAL SA Filed SC 13G/A on 60 DEGREES PHARMACEUTICALS, INC., latest May 7, 2024 (2 filings since Dec 18, 2023)
  • 60 DEGREES PHARMACEUTICALS, INC. Washington, the District of Columbia

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What 60 DEGREES PHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$55.8K5 Dec 31, 2024
Property and equipment, before depreciation$437.2K3 Dec 31, 2025$299.2K3 Dec 31, 2024+46.1%
Accumulated depreciation$190.9K3 Dec 31, 2025$149.4K3 Dec 31, 2024+27.7%
Property and equipment, net$246.4K3 Dec 31, 2025$149.8K3 Dec 31, 2024+64.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.5M3 Dec 31, 2025$1.7M3 Dec 31, 2024−9.0%
Marketable securities, current$1.2M3 Dec 31, 2025$1.7M3 Dec 31, 2024−28.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$224.4K3 Dec 31, 2025$157.1K3 Dec 31, 2024+42.8%
Finite-lived intangibles, gross$339.1K3 Dec 31, 2025$232.2K3 Dec 31, 2024+46.0%
Accumulated amortization$114.7K3 Dec 31, 2025$75.1K3 Dec 31, 2024+52.6%
Patents, net$207.4K3 Dec 31, 2025$127.6K3 Dec 31, 2024+62.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$656.9K3 Dec 31, 2025$442.8K3 Dec 31, 2024+48.4%
Raw materials$75.7K3 Dec 31, 2025$03 Dec 31, 2024
Work in process$447.0K3 Dec 31, 2025$284.9K3 Dec 31, 2024+56.9%
Finished goods$386.0K3 Dec 31, 2025$157.9K3 Dec 31, 2024+144.5%

Properties, in its own words

Our corporate headquarters are located at 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036. We do not own any physical property, plant or labs. We currently lease one office at the above address, which lease was recently renewed for an additional one-year term expiring on March 31, 2027.

Item 2 of the 10-K filed Mar 30, 2026.8

Leadership

Who has led 60 DEGREES PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Geoffrey S. Dow2023–now

President

  1. Geoffrey S. Dow2023–now

Chief financial officer

  1. Tyrone Miller2023–2025

Chief operating officer

  1. Kristen Landon2025–now
2025
Board members and other officers (6)

Timeline

  1. Oct 6, 20268-K Regulation FD disclosure; Other events17
  2. Sep 14, 20268-K Other events18
  3. Sep 8, 20268-K Regulation FD disclosure19
  4. Aug 6, 20268-K Shareholder vote20
  5. Aug 4, 20268-K Entered a material agreement; Unregistered sale of shares; Other events21
  6. Jul 20, 20268-K Regulation FD disclosure22
  7. Jul 9, 20268-K Other events23
  8. Jun 3, 20268-K Other events24
  9. May 18, 20268-K Executive or director change25
  10. Mar 20, 20268-K Other events26
  11. Mar 13, 20268-K Other events27
  12. Mar 12, 20268-K Other events28
  13. Jul 11, 2023New chief executive Geoffrey S. Dow becomes CEO9

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($2.64) a share, on Nov 13, 2025.29

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

220 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 47 major events, 40 insider forms, 21 large holders, 3 private raises, 96 other. The latest 20:

  1. Oct 6, 20268-K CURRENT REPORT EDGAR
  2. Sep 14, 20268-K CURRENT REPORT EDGAR
  3. Sep 8, 20268-K CURRENT REPORT EDGAR
  4. Aug 25, 2026EFFECT EDGAR
  5. Aug 17, 2026DEL AM DELAYING AMENDMENT EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Aug 14, 2026S-3 REGISTRATION STATEMENT EDGAR
  8. Aug 6, 20268-K CURRENT REPORT EDGAR
  9. Aug 5, 2026SCHEDULE 13G EDGAR
  10. Aug 4, 20268-K CURRENT REPORT EDGAR
  11. Jul 29, 20263 EDGAR
  12. Jul 29, 2026SCHEDULE 13G EDGAR
  13. Jul 20, 20268-K CURRENT REPORT EDGAR
  14. Jul 9, 20268-K CURRENT REPORT EDGAR
  15. Jul 2, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  16. Jun 15, 20264 EDGAR
  17. Jun 8, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  18. Jun 3, 20268-K CURRENT REPORT EDGAR
  19. May 19, 20263 EDGAR
  20. May 18, 20268-K CURRENT REPORT EDGAR

The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 17 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 12, 2026DOW GEOFFREY SPresident and CEOBuy7,350$1.38$10.1KForm 4
Dec 15, 2025DOW GEOFFREY SPresident and CEOBuy9,670$0.80$7.7KForm 4
Dec 11, 2025DOW GEOFFREY SPresident and CEOBuy3,613$0.92$3.3KForm 4
Dec 10, 2025DOW GEOFFREY SPresident and CEOBuy9,350$0.95$8.9KForm 4
Jun 3, 2025XU CHERYLDirectorBuy5,000$2.88$14.4KForm 4
Dec 16, 2024XU CHERYLDirectorBuy2,000$1.45$2.9KForm 4
Dec 13, 2024XU CHERYLDirectorBuy6,000$1.56$9.4KForm 4
Dec 12, 2024XU CHERYLDirectorBuy5,000$1.82$9.1KForm 4
Dec 9, 2024DOW GEOFFREY SPresident and CEOBuy35,823$1.27$45.5KForm 4
Dec 6, 2024DOW GEOFFREY SPresident and CEOBuy20,579$1.20$24.7KForm 4
Dec 5, 2024DOW GEOFFREY SPresident and CEOBuy17,549$1.11$19.5KForm 4
Nov 21, 2024DOW GEOFFREY SPresident and CEOBuy3,500$0.91$3.2KForm 4
Nov 20, 2024DOW GEOFFREY SPresident and CEOBuy1,000$0.92$920Form 4
Nov 19, 2024DOW GEOFFREY SPresident and CEOBuy2,500$0.90$2.2KForm 4
Aug 27, 2024XU CHERYLDirectorBuy5,000$1.70$8.5KForm 4
Jan 31, 2024DOW GEOFFREY SPresident and CEOBuy25,974$0.38$9.9KForm 4
Jan 31, 2024XU CHERYLDirectorBuy200,000$0.38$76.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Geoffrey Dow52$250.0K$727.8K38
2025Kristen Landon59$300.0K$311.8K38
2025Tyrone Miller52$215.0K$283.2K38
2024Chief Commercial Officer$300.0K$470.9K38
2024President and Chief Executive Officer$228.0K$323.4K38
2024Chief Financial Officer$204.0K$284.5K38
2023(Principal Financial and Accounting Officer)$135.6K38
2023(Principal Executive Officer)$125.6K38

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 5, 2025Raised $1.1 million in a private offering of securities Form D: 4 investors so far Form D
  2. Jan 28, 2025Raised $1 million in a private offering of securities Form D: 4 investors so far Form D
  3. May 19, 2022Raised $1.8 million in a private offering of securities Form D: 10 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Kathmere Capital Management, LLC265,100$466.6K0.0%+120,417
Citadel Advisors LLC22,362$39.4K0.0%New
XTX Topco Ltd17,639$31.0K0.0%New
Kovack Advisors, Inc.15,000$26.4K0.0%New
Geode Capital Management, LLC14,551$25.6K0.0%−1,744
UBS Group AG13,592$23.9K0.0%−17,818
Barclays PLC1,052$1.9K0.0%−804
Osaic Holdings, Inc.25$440.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How 60 DEGREES PHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAR60 DEGREES PHARMACEUTICALS, INC.1
  • CIK0001946563
  • Employer ID (EIN)45-24068808
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company8
  • Incorporated inDelaware8
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1025 Connecticut Avenue Nw, Suite 1000, Washington, DC 200361
  • Phone202-327-54221
  • Shares outstanding3,516,988 as of Aug 14, 20267
  • Public float$3.3M as of Jun 30, 20258
  • AuditorRBSM LLP, Las Vegas, Nevada PCAOB ID 587; no auditor attestation of internal control over financial reporting8
  • On EDGAR sinceOct 18, 20221
  • Filings220 in all: 8-K (47), 4 (27), CORRESP (26), 3 (13), UPLOAD (13), 10-Q (10), 424B5 (10), SCHEDULE 13G/A (9)1
    All 30 form types

    SCHEDULE 13G (8), EFFECT (7), S-1/A (6), DEF 14A (4), PRE 14A (4), S-1 (4), 10-K (3), 424B4 (3), D (3), DRS (3), S-3 (3), 8-A12B/A (2), DRS/A (2), DRSLTR (2), SC 13G (2), SC 13G/A (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), DEFR14A (1), DEL AM (1), NT 10-Q (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jul 2, 2026
    Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareSXTPNasdaq
Warrants, each warrant to purchase one share of Common StockSXTPWNasdaq

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).8

Risk factors and legal proceedings

Legal proceedings

From time to time, we may become involved in various claims and legal proceedings. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.8

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    SEC EDGAROther events
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
    SEC EDGAROther events
  24. 24
    SEC EDGAROther events
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
    SEC EDGAROther events
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38